The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
Mario Sznol
Disclosure not yet available
Harriet M. Kluger
Disclosure not yet available
Margaret K. Callahan
Disclosure not yet available
Michael Andrew Postow
Disclosure not yet available
Ruth Ann Gordon
Disclosure not yet available
Neil Howard Segal
Disclosure not yet available
Naiyer A. Rizvi
Disclosure not yet available
Alexander M. Lesokhin
Disclosure not yet available
Michael B. Atkins
Disclosure not yet available
John M. Kirkwood
Disclosure not yet available
Matthew M. Burke
Disclosure not yet available
Amanda L. Ralabate
Disclosure not yet available
Angel L. Rivera
Disclosure not yet available
Stephanie Anne Kronenberg
Disclosure not yet available
Blessing Agunwamba
Disclosure not yet available
William Feely
Disclosure not yet available
Quan Hong
Disclosure not yet available
Suba Krishnan
Disclosure not yet available
Ashok Kumar Gupta
Disclosure not yet available
Jedd D. Wolchok
Disclosure not yet available